Clinical Trial Update: Erythrocytapheresis Versus Phlebotomy as Maintenance Therapy in Hereditary Hemochromatosis (HH) Patients [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial update comparing erythrocytapheresis to phlebotomy as maintenance therapy in hereditary hemochromatosis.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hereditary Hemochromatosis

Drugs mentioned

• Erythrocytapheresis
• Phlebotomy

Snippet

Sponsor: Sanquin Research & Blood Bank Divisions | Conditions: Hereditary Hemochromatosis | Phase 3 | Status: UNKNOWN